Not currently recruiting at UCLA
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Augustine Chung
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Augustine Chung
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 8 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- GlaxoSmithKline
- ID
- NCT06572384
- Phase
- Phase 3 Interstitial Lung Disease Research Study
- Study Type
- Interventional
- Participants
- Expecting 440 study participants
- Last Updated